Dr David Henry's top ASCO selections in hematology and bone healthAugust 15, 2018Lymphoma & Plasma Cell Disorders
New myeloma drugs improve response and extend survivalAugust 15, 2018Lymphoma & Plasma Cell Disorders
First CAR T-cell therapy approvals bolster booming immunotherapy marketAugust 15, 2018Lymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, Transplantation
An unusual case of primary cardiac prosthetic valve-associated lymphomaAugust 15, 2018Lymphoma & Plasma Cell DisordersPatient & Survivor Care
Meeting the potential of immunotherapy: new targets provide rational combinationsAugust 15, 2018GastroenterologyBreast CancerGenitourinary CancerHead & Neck/Thyroid CancersImmunotherapyLymphoma & Plasma Cell DisordersMelanoma
Durable response to pralatrexate for aggressive PTCL subtypesAugust 15, 2018Lymphoma & Plasma Cell DisordersPatient & Survivor Care
New myeloma drugs improve response and extend survivalAugust 15, 2018Lymphoma & Plasma Cell DisordersPatient & Survivor Care
Immunotherapies shape the treatment landscape for hematologic malignanciesAugust 15, 2018Lymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, TransplantationImmunotherapy
Lenalidomide becomes standard of care for multiple myeloma in the maintenance settingAugust 2, 2018Lymphoma & Plasma Cell Disorders
CAR T-cell approvals: multiple myeloma likely next upJune 21, 2018Lymphoma & Plasma Cell DisordersPatient & Survivor Care
